1
|
Abramson DH, Shields CL, Munier FL and
Chantada GL: Treatment of retinoblastoma in 2015: Agreement and
disagreement. JAMA Ophthalmol. 133:1341–1347. 2015. View Article : Google Scholar : PubMed/NCBI
|
2
|
Broaddus E, Topham A and Singh AD:
Incidence of retinoblastoma in the USA: 1975–2004. Br J Ophthalmol.
93:21–23. 2009. View Article : Google Scholar : PubMed/NCBI
|
3
|
Kleinerman RA, Schonfeld SJ and Tucker MA:
Sarcomas in hereditary retinoblastoma. Clin Sarcoma Res. 2:152012.
View Article : Google Scholar : PubMed/NCBI
|
4
|
Marees T, Moll AC, Imhof SM, de Boer MR,
Ringens PJ and van Leeuwen FE: Risk of second malignancies in
survivors of retinoblastoma: More than 40 years of follow-up. J
Natl Cancer Inst. 100:1771–1779. 2008. View Article : Google Scholar : PubMed/NCBI
|
5
|
Moll AC, Imhof SM, Bouter LM and Tan KE:
Second primary tumors in patients with retinoblastoma. A review of
the literature. Ophthalmic Genet. 18:27–34. 1997. View Article : Google Scholar : PubMed/NCBI
|
6
|
Benavente CA and Dyer MA: Genetics and
epigenetics of human retinoblastoma. Annu Rev Pathol. 10:547–562.
2015. View Article : Google Scholar : PubMed/NCBI
|
7
|
Yang YQ, Li J and Yuan HF: Epidemiology
and risk factors of retinoblastoma in Chongqing area. Int J
Ophthalmol. 9:984–988. 2016.PubMed/NCBI
|
8
|
Finger PT, Harbour JW and Karcioglu ZA:
Risk factors for metastasis in retinoblastoma. Surv Ophthalmol.
47:1–16. 2002. View Article : Google Scholar : PubMed/NCBI
|
9
|
Friedman DL, Himelstein B, Shields CL,
Shields JA, Needle M, Miller D, Bunin GR and Meadows AT:
Chemoreduction and local ophthalmic therapy for intraocular
retinoblastoma. J Clin Oncol. 18:12–17. 2000. View Article : Google Scholar : PubMed/NCBI
|
10
|
Dimaras H, Kimani K, Dimba EA, Gronsdahl
P, White A, Chan HS and Gallie BL: Retinoblastoma. Lancet.
379:1436–1446. 2012. View Article : Google Scholar : PubMed/NCBI
|
11
|
Kaliki S, Shields CL, Rojanaporn D,
Al-Dahmash S, McLaughlin JP, Shields JA and Eagle RC Jr: High-risk
retinoblastoma based on international classification of
retinoblastoma: Analysis of 519 enucleated eyes. Ophthalmology.
120:997–1003. 2013. View Article : Google Scholar : PubMed/NCBI
|
12
|
Ha M and Kim VN: Regulation of microRNA
biogenesis. Nat Rev Mol Cell Biol. 15:509–524. 2014. View Article : Google Scholar : PubMed/NCBI
|
13
|
Kozomara A and Griffiths-Jones S: miRBase:
Integrating microRNA annotation and deep-sequencing data. Nucleic
Acids Res. 39(Database Issue): D152–D157. 2011. View Article : Google Scholar : PubMed/NCBI
|
14
|
Bartel DP: MicroRNAs: Genomics,
biogenesis, mechanism, and function. Cell. 116:281–297. 2004.
View Article : Google Scholar : PubMed/NCBI
|
15
|
Baranwal S and Alahari SK: miRNA control
of tumor cell invasion and metastasis. Int J Cancer. 126:1283–1290.
2010.PubMed/NCBI
|
16
|
Iorio MV and Croce CM: MicroRNA
dysregulation in cancer: Diagnostics, monitoring and therapeutics.
A comprehensive review. EMBO Mol Med. 4:143–159. 2012. View Article : Google Scholar : PubMed/NCBI
|
17
|
Calin GA and Croce CM: MicroRNA signatures
in human cancers. Nat Rev Cancer. 6:857–866. 2006. View Article : Google Scholar : PubMed/NCBI
|
18
|
Gao HY, Huo FC, Wang HY and Pei DS:
MicroRNA-9 inhibits the gastric cancer cell proliferation by
targeting TNFAIP8. Cell Prolif. 50:2017. View Article : Google Scholar
|
19
|
Li C, Lu S and Shi Y: MicroRNA-187
promotes growth and metastasis of gastric cancer by inhibiting
FOXA2. Oncol Rep. 37:1747–1755. 2017. View Article : Google Scholar : PubMed/NCBI
|
20
|
Zeng Y, Zhu J, Shen D, Qin H, Lei Z, Li W,
Liu Z and Huang JA: MicroRNA-205 targets SMAD4 in non-small cell
lung cancer and promotes lung cancer cell growth in vitro and in
vivo. Oncotarget. 8:30817–30829. 2017.PubMed/NCBI
|
21
|
Dong F, Xu T, Shen Y, Zhong S, Chen S,
Ding Q and Shen Z: Dysregulation of miRNAs in bladder cancer:
Altered expression with aberrant biogenesis procedure. Oncotarget.
8:27547–27568. 2017.PubMed/NCBI
|
22
|
Wang LL, Hu HF and Feng YQ: Suppressive
effect of microRNA-143 in retinoblastoma. Int J Ophthalmol.
9:1584–1590. 2016.PubMed/NCBI
|
23
|
Hwang HW and Mendell JT: MicroRNAs in cell
proliferation, cell death, and tumorigenesis. Br J Cancer. 96
Suppl:R40–R44. 2007.PubMed/NCBI
|
24
|
Han RL, Wang FP, Zhang PA, Zhou XY and Li
Y: miR-383 inhibits ovarian cancer cell proliferation, invasion and
aerobic glycolysis by targeting LDHA. Neoplasma. 64:244–252. 2017.
View Article : Google Scholar : PubMed/NCBI
|
25
|
Li B, Xie Z, Li Z, Chen S and Li B:
MicroRNA-613 targets FMNL2 and suppresses progression of colorectal
cancer. Am J Transl Res. 8:5475–5484. 2016.PubMed/NCBI
|
26
|
Sun Z, Zhang A, Jiang T, Du Z, Che C and
Wang F: MiR-145 suppressed human retinoblastoma cell proliferation
and invasion by targeting ADAM19. Int J Clin Exp Pathol.
8:14521–14527. 2015.PubMed/NCBI
|
27
|
Montoya V, Fan H, Bryar PJ, Weinstein JL,
Mets MB, Feng G, Martin J, Martin A, Jiang H and Laurie NA: Novel
miRNA-31 and miRNA-200a-mediated regulation of retinoblastoma
proliferation. PLoS One. 10:e01383662015. View Article : Google Scholar : PubMed/NCBI
|
28
|
Shen F, Mo MH, Chen L, An S, Tan X, Fu Y,
Rezaei K, Wang Z, Zhang L and Fu SW: MicroRNA-21 down-regulates Rb1
expression by targeting PDCD4 in retinoblastoma. J Cancer.
5:804–812. 2014. View Article : Google Scholar : PubMed/NCBI
|
29
|
Chen T, Ren H, Thakur A, Yang T, Li Y,
Zhang S, Wang T and Chen M: miR-382 inhibits tumor progression by
targeting SETD8 in non-small cell lung cancer. Biomed Pharmacother.
86:248–253. 2017. View Article : Google Scholar : PubMed/NCBI
|
30
|
Zhou B, Song J, Han T, Huang M, Jiang H,
Qiao H, Shi J and Wang Y: MiR-382 inhibits cell growth and invasion
by targeting NR2F2 in colorectal cancer. Mol Carcinog.
55:2260–2267. 2016. View
Article : Google Scholar : PubMed/NCBI
|
31
|
Ho JY, Hsu RJ, Liu JM, Chen SC, Liao GS,
Gao HW and Yu CP: MicroRNA-382-5p aggravates breast cancer
progression by regulating the RERG/Ras/ERK signaling axis.
Oncotarget. 8:22443–22459. 2017.PubMed/NCBI
|
32
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
33
|
Stephan H, Zakrzewski JL, Bölöni R,
Grasemann C, Lohmann DR and Eggert A: Neurotrophin receptor
expression in human primary retinoblastomas and retinoblastoma cell
lines. Pediatr Blood Cancer. 50:218–222. 2008. View Article : Google Scholar : PubMed/NCBI
|
34
|
Shang W, Yang Y, Zhang J and Wu Q: Long
noncoding RNA BDNF-AS is a potential biomarker and regulates cancer
development in human retinoblastoma. Biochem Biophys Res Commun.
Jan 26–2017.(Epub ahead of print). View Article : Google Scholar
|
35
|
Mao XY, Zhou HH, Li X and Liu ZQ:
Huperzine A alleviates oxidative glutamate toxicity in hippocampal
HT22 cells via activating BDNF/TrkB-dependent PI3K/Akt/mTOR
signaling pathway. Cell Mol Neurobiol. 36:915–925. 2016. View Article : Google Scholar : PubMed/NCBI
|
36
|
Xia H, Li Y and Lv X: MicroRNA-107
inhibits tumor growth and metastasis by targeting the BDNF-mediated
PI3K/AKT pathway in human non-small lung cancer. Int J Oncol.
49:1325–1333. 2016.PubMed/NCBI
|
37
|
Huang Q, Liu L, Liu CH, You H, Shao F, Xie
F, Lin XS, Hu SY and Zhang CH: MicroRNA-21 regulates the invasion
and metastasis in cholangiocarcinoma and may be a potential
biomarker for cancer prognosis. Asian Pac J Cancer Prev.
14:829–834. 2013. View Article : Google Scholar : PubMed/NCBI
|
38
|
Yu SH, Zhang CL, Dong FS and Zhang YM:
miR-99a suppresses the metastasis of human non-small cell lung
cancer cells by targeting AKT1 signaling pathway. J Cell Biochem.
116:268–276. 2015. View Article : Google Scholar : PubMed/NCBI
|
39
|
Funamizu N, Lacy CR, Parpart ST, Takai A,
Hiyoshi Y and Yanaga K: MicroRNA-301b promotes cell invasiveness
through targeting TP63 in pancreatic carcinoma cells. Int J Oncol.
44:725–734. 2014. View Article : Google Scholar : PubMed/NCBI
|
40
|
Wu X, Zeng Y, Wu S, Zhong J, Wang Y and Xu
J: MiR-204, down-regulated in retinoblastoma, regulates
proliferation and invasion of human retinoblastoma cells by
targeting CyclinD2 and MMP-9. FEBS Lett. 589:645–650. 2015.
View Article : Google Scholar : PubMed/NCBI
|
41
|
Wang J, Wang X, Wu G, Hou D and Hu Q:
MiR-365b-3p, down-regulated in retinoblastoma, regulates cell cycle
progression and apoptosis of human retinoblastoma cells by
targeting PAX6. FEBS Lett. 587:1779–1786. 2013. View Article : Google Scholar : PubMed/NCBI
|
42
|
Xu M, Jin H, Xu CX, Sun B, Song ZG, Bi WZ
and Wang Y: miR-382 inhibits osteosarcoma metastasis and relapse by
targeting Y box-binding protein 1. Mol Ther. 23:89–98. 2015.
View Article : Google Scholar : PubMed/NCBI
|
43
|
Qi B, Lu JG, Yao WJ, Chang TM, Qin XG, Ji
YH, Wang TY, Liu SG, Li HC, Liu YZ and Zhao BS: Downregulation of
microRNA-382 is associated with poor outcome of esophageal squamous
cell carcinoma. World J Gastroenterol. 21:6884–6891. 2015.
View Article : Google Scholar : PubMed/NCBI
|
44
|
Zhang W, Liu J, Qiu J, Fu X, Tang Q, Yang
F, Zhao Z and Wang H: MicroRNA-382 inhibits prostate cancer cell
proliferation and metastasis through targeting COUP-TFII. Oncol
Rep. 36:3707–3715. 2016. View Article : Google Scholar : PubMed/NCBI
|
45
|
Tan H, He Q, Gong G, Wang Y, Li J, Wang J,
Zhu D and Wu X: miR-382 inhibits migration and invasion by
targeting ROR1 through regulating EMT in ovarian cancer. Int J
Oncol. 48:181–190. 2016. View Article : Google Scholar : PubMed/NCBI
|
46
|
Xu M, Jin H, Xu CX, Sun B, Mao Z, Bi WZ
and Wang Y: miR-382 inhibits tumor growth and enhance
chemosensitivity in osteosarcoma. Oncotarget. 5:9472–9483. 2014.
View Article : Google Scholar : PubMed/NCBI
|
47
|
Yu Z, Ni L, Chen D, Zhang Q, Su Z, Wang Y,
Yu W, Wu X, Ye J, Yang S, et al: Identification of miR-7 as an
oncogene in renal cell carcinoma. J Mol Histol. 44:669–677. 2013.
View Article : Google Scholar : PubMed/NCBI
|
48
|
McAllister AK: Neurotrophins and neuronal
differentiation in the central nervous system. Cell Mol Life Sci.
58:1054–1060. 2001. View Article : Google Scholar : PubMed/NCBI
|
49
|
Lai PC, Chiu TH and Huang YT:
Overexpression of BDNF and TrkB in human bladder cancer specimens.
Oncol Rep. 24:1265–1270. 2010.PubMed/NCBI
|
50
|
Choi B, Lee EJ, Shin MK, Park YS, Ryu MH,
Kim SM, Kim EY, Lee HK and Chang EJ: Upregulation of brain-derived
neurotrophic factor in advanced gastric cancer contributes to bone
metastatic osteolysis by inducing long pentraxin 3. Oncotarget.
7:55506–55517. 2016. View Article : Google Scholar : PubMed/NCBI
|
51
|
Yang X, Martin TA and Jiang WG: Biological
influence of brain-derived neurotrophic factor (BDNF) on colon
cancer cells. Exp Ther Med. 6:1475–1481. 2013. View Article : Google Scholar : PubMed/NCBI
|
52
|
Yang X, Martin TA and Jiang WG: Biological
influence of brain-derived neurotrophic factor on breast cancer
cells. Int J Oncol. 41:1541–1546. 2012. View Article : Google Scholar : PubMed/NCBI
|
53
|
Huang SM, Lin C, Lin HY, Chiu CM, Fang CW,
Liao KF, Chen DR and Yeh WL: Brain-derived neurotrophic factor
regulates cell motility in human colon cancer. Endocr Relat Cancer.
22:455–464. 2015. View Article : Google Scholar : PubMed/NCBI
|
54
|
Zhang SY, Hui LP, Li CY, Gao J, Cui ZS and
Qiu XS: More expression of BDNF associates with lung squamous cell
carcinoma and is critical to the proliferation and invasion of lung
cancer cells. BMC Cancer. 16:1712016. View Article : Google Scholar : PubMed/NCBI
|